Angel News

Back to Homepage

8th July 2020

ProFactor Pharma completes milestone towards treatment of Haemophilia A

Kelvin Capital backed ProFactor Pharma Ltd (PFP), has completed an important development milestone in its research that will transform the treatment of ‘Haemophilia A’.

Based outside Edinburgh at the Easter Bush Campus, the company has received £1.1m (the second tranche of funding from its £2m funding round announced in September 2019) to advance its R&D programme, which is moving closer to toxicology studies for its low cost recombinant human factor VIII (rhFVIII) for the treatment of ‘Haemophilia A’.


Register / Login now to read full story

In order to read the full story we need you to be registered with us, please click the links below to login or register.

Login / Register

Add a comment:




Enter the characters in the image shown:

Back to Homepage